624. Hodgkin Lymphomas: Clinical and Epidemiological: Poster I

Low dose nivolumab combined with AVD chemotherapy Nivo40 AVD for advanced stage classic Hodgkin lymphoma

Dose Escalation  shows no benefit compared to continuing ABVD in Hodgkin s lymphoma patients with an interim PET deauville score of 4

Treatment options responses and outcome of 1220 classic Hodgkin lymphoma patients included in realysa a prospective multicentric lysa cohort

Real world clinical outcomes with novel agent combination therapies for the frontline treatment of pediatric and adult advanced stage Hodgkin lymphoma

Pembrolizumab plus gemcitabine vinorelbine and liposomal doxorubicin as second line therapy in relapsed or refractory Hodgkin lymphoma 5 year update of a multicenter Phase 2 trial

Age related differences in presentation among pediatric adolescent and young adults with mixed cellularity vs nodular sclerosis histology Hodgkin lymphoma on Children s oncology group treatment and registry trials

Bendamustine gemcitabine and vinorelbine BeGEV regimen followed by ASCT Induces Durable Remissions in PD L 1 inhibitor resistant Refractory relapsed classical Hodgkin lymphoma A single center long term study

Safety and efficacy of MT 601 in relapsed or refractory r r Hodgkin lymphoma

External validation of the early stage classic Hodgkin lymphoma cHL international prognostication index E HIPI in the german Hodgkin study group GHSG unfavorable clinical trials

Autologous CD30 CAR T cell therapy in patients with relapsed or refractory classical Hodgkin lymphoma – long term update of the chariot trial